Form 4: Heron Therapeutics Director Acquires Shares and Options in Recent Transaction

Director Christian Waage of Heron Therapeutics acquired 17,950 shares of common stock and 35,900 stock options on January 30, 2025.

Summary

• Christian Waage, a director at Heron Therapeutics, acquired 17,950 shares of common stock and 35,900 stock options on January 30, 2025.
• The shares were granted as restricted stock units that will vest on January 30, 2026.
• Each restricted stock unit represents the right to receive one share of common stock.
• The stock options vest in 12 equal monthly installments starting one month after the grant date and expire on January 30, 2035.
• The exercise price for the stock options is $1.73 per share.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of insider transactions, which is neither particularly positive nor negative. The acquisition of shares and options by a director is a neutral event.

Positives

• The acquisition of shares and options by a director could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• The transaction is typical for directors of publicly traded companies, who often receive stock options and restricted stock units as part of their compensation.
• The vesting schedule for the restricted stock units and stock options is also standard practice.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's confidence in the company.

Key Dates

Keywords

Heron Therapeutics, HRTX, insider trading, stock options, restricted stock units, director, equity, share acquisition